Largest pharmaceuticals by total liabilities
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
AbbVie leads the 61 pharmaceuticals ranked by total liabilities, at SAR 514.6B, ahead of Pfizer (SAR 455.3B) and Johnson & Johnson (SAR 441.4B). Figures as of 18 Nov 2026, 14:28 UTC, from Yahoo Finance quotes.
Key facts
- Companies ranked
- 61
- First
- AbbVieSAR 514.6B
- Median
- SAR 7.8B
- Combined market value
- SAR 19.35T
- Countries
- 10
Market values as of .
All countries▾
All sectors▾
Pharmaceuticals▾
| # | Company | Total liabilities ↓ | Market cap | Price | Today | 1 year | Price, 30 days | Country |
|---|---|---|---|---|---|---|---|---|
| 1 | AbbVieABBV · Health Care | SAR 514.6B | SAR 1.94T | SAR 1,098.37 | 0.59% down | 26% up | ||
| 2 | PfizerPFE · Health Care | SAR 455.3B | SAR 608.7B | SAR 106.79 | 1.35% down | 14% up | ||
| 3 | Johnson & JohnsonJNJ · Health Care | SAR 441.4B | SAR 2.52T | SAR 1,045.40 | 1.36% down | 38% up | ||
| 4 | Eli LillyLLY · Health Care | SAR 322.4B | SAR 4.73T | SAR 5,309.73 | 1.13% down | 35% up | ||
| 5 | Merck & CoMRK · Health Care | SAR 315.8B | SAR 1.33T | SAR 537.78 | 0.75% down | 51% up | ||
| 6 | Bristol-Myers SquibbBMY · Health Care | SAR 268.3B | SAR 470.4B | SAR 230.12 | 2.51% down | 34% up | ||
| 7 | AstraZenecaAZN · Health Care | SAR 245.1B | SAR 1.06T | SAR 683.69 | 0.95% down | 2% up | ||
| 8 | NovartisNVS · Health Care | SAR 241.6B | SAR 1.13T | SAR 596.90 | 0.67% down | 25% up | ||
| 9 | SanofiSNY · Health Care | SAR 229.3B | SAR 428.1B | SAR 178.29 | 1.78% down | 4% down | ||
| 10 | GSKGSK · Health Care | SAR 224.9B | SAR 370.2B | SAR 184.70 | 2.32% down | 6% up | ||
| 11 | Novo NordiskNVO · Health Care | SAR 194.2B | SAR 672.9B | SAR 152.67 | 2.16% down | 17% down | ||
| 12 | Takeda PharmaceuticalTAK · Health Care | SAR 189.8B | SAR 259.3B | SAR 81.17 | 0.23% up | 54% up | ||
| 13 | Abbott LaboratoriesABT · Health Care | SAR 127.3B | SAR 680.2B | SAR 392.77 | 2.55% down | 17% down | ||
| 14 | Teva Pharmaceutical IndustriesTEVA · Health Care | SAR 123.2B | SAR 186.5B | SAR 159.87 | 0.12% up | 74% up | ||
| 15 | ViatrisVTRS · Health Care | SAR 84.3B | SAR 87.9B | SAR 76.71 | 1.40% down | 96% up | ||
| 16 | GrifolsGRFS · Health Care | SAR 50.4B | SAR 22B | SAR 32.37 | 1.15% down | 1% up | ||
| 17 | ZoetisZTS · Health Care | SAR 45.5B | SAR 127.2B | SAR 313.13 | 1.08% down | 29% down | ||
| 18 | Royalty PharmaRPRX · Health Care | SAR 37.2B | SAR 148.1B | SAR 257.62 | 0.23% up | 78% up | ||
| 19 | Regeneron PharmaceuticalsREGN · Health Care | SAR 34.9B | SAR 371.6B | SAR 3,592.56 | 0.56% up | 36% up | ||
| 20 | Jazz PharmaceuticalsJAZZ · Health Care | SAR 27.5B | SAR 58B | SAR 902.90 | 0.39% up | 37% up | ||
| 21 | GenmabGMAB · Health Care | SAR 26.4B | SAR 120.2B | SAR 194.90 | 0.76% up | 70% up | ||
| 22 | Vertex PharmaceuticalsVRTX · Health Care | SAR 26.2B | SAR 508B | SAR 2,003.78 | 0.67% down | 27% up | ||
| 23 | Elanco Animal HealthELAN · Health Care | SAR 25.5B | SAR 48.5B | SAR 96.96 | 2.12% down | 20% up | ||
| 24 | Alnylam PharmaceuticalsALNY · Health Care | SAR 15.7B | SAR 78.6B | SAR 587.03 | 2.02% down | 66% down | ||
| 25 | BeOne MedicinesONC · Health Care | SAR 14.4B | SAR 177.1B | SAR 1,550.14 | 0.48% up | 17% up | ||
| 26 | Amneal PharmaceuticalsAMRX · Health Care | SAR 13.8B | SAR 27.6B | SAR 79.22 | 0.52% down | 83% up | ||
| 27 | PTC TherapeuticsPTCT · Health Care | SAR 11.6B | SAR 18.9B | SAR 226.41 | 1.00% down | 20% down | ||
| 28 | Ionis PharmaceuticalsIONS · Health Care | SAR 11.4B | SAR 16.8B | SAR 101.13 | 3.75% down | 64% down | ||
| 29 | BridgeBio PharmaBBIO · Health Care | SAR 11.3B | SAR 56.1B | SAR 288.08 | 0.72% down | 17% up | ||
| 30 | Dr. Reddy's LaboratoriesRDY · Health Care | SAR 7.9B | SAR 46.2B | SAR 55.48 | 0.61% up | 5% up | ||
| 31 | CytokineticsCYTK · Health Care | SAR 7.8B | SAR 27B | SAR 193.74 | 2.86% down | 20% down | ||
| 32 | Ascendis PharmaASND · Health Care | SAR 6.1B | SAR 66.7B | SAR 1,017.23 | 0.20% down | 28% up | ||
| 33 | InsmedINSM · Health Care | SAR 5.7B | SAR 100.3B | SAR 457.10 | 0.83% down | 40% down | ||
| 34 | BioMarin PharmaceuticalBMRN · Health Care | SAR 5.7B | SAR 42.5B | SAR 219.47 | 0.90% up | 11% up | ||
| 35 | Arrowhead PharmaceuticalsARWR · Health Care | SAR 3.3B | SAR 22.8B | SAR 161.26 | 2.76% down | 10% up | ||
| 36 | United TherapeuticsUTHR · Health Care | SAR 2.9B | SAR 93.3B | SAR 2,190.96 | 0.64% down | 23% up | ||
| 37 | Legend BiotechLEGN · Health Care | SAR 2.7B | SAR 11.7B | SAR 60.43 | 0.75% up | 42% down | ||
| 38 | AlkermesALKS · Health Care | SAR 2.5B | SAR 28.6B | SAR 170.48 | 2.32% down | 58% up | ||
| 39 | Madrigal PharmaceuticalsMDGL · Health Care | SAR 2.5B | SAR 36.8B | SAR 1,582.88 | 0.46% down | 24% down | ||
| 40 | Axsome TherapeuticsAXSM · Health Care | SAR 2.3B | SAR 26.8B | SAR 509.95 | 0.77% down | 7% down | ||
| 41 | Ligand PharmaceuticalsLGND · Health Care | SAR 2B | SAR 22B | SAR 1,102.08 | 2.62% down | 43% up | ||
| 42 | Mirum PharmaceuticalsMIRM · Health Care | SAR 2B | SAR 22.5B | SAR 344.90 | 0.40% up | 31% up | ||
| 43 | Travere TherapeuticsTVTX · Health Care | SAR 1.8B | SAR 18.4B | SAR 191.68 | 2.82% up | 44% up | ||
| 44 | Roivant SciencesROIV · Health Care | SAR 1.6B | SAR 105.2B | SAR 145.20 | 0.26% up | 90% up | ||
| 45 | TG TherapeuticsTGTX · Health Care | SAR 1.6B | SAR 35.6B | SAR 235.23 | 0.08% down | 107% up | ||
| 46 | Cogent BiosciencesCOGT · Health Care | SAR 1.1B | SAR 18.2B | SAR 104.47 | 1.49% up | 20% down | ||
| 47 | Rhythm PharmaceuticalsRYTM · Health Care | SAR 788.3M | SAR 30.3B | SAR 437.40 | 8.49% up | 13% up | ||
| 48 | Kiniksa Pharmaceuticals InternationalKNSA · Health Care | SAR 735.3M | SAR 28B | SAR 356.76 | 0.93% up | 126% up | ||
| 49 | Corcept TherapeuticsCORT · Health Care | SAR 708.4M | SAR 28.8B | SAR 262.83 | 1.23% up | 8% down | ||
| 50 | ABIVAXABVX · Health Care | SAR 537.4M | SAR 27B | SAR 307.96 | 1.81% down | 27% down | ||
| 51 | Definium TherapeuticsDFTX · Health Care | SAR 404.3M | SAR 15.1B | SAR 110.20 | 2.59% down | 169% up | ||
| 52 | Summit TherapeuticsSMMT · Health Care | SAR 346.3M | SAR 32B | SAR 40.02 | 9.73% down | 36% down | ||
| 53 | ErascaERAS · Health Care | SAR 266.3M | SAR 18.3B | SAR 52.10 | 8.07% down | 403% up | ||
| 54 | Spyre TherapeuticsSYRE · Health Care | SAR 234.6M | SAR 33.4B | SAR 351.88 | 5.60% down | 286% up | ||
| 55 | Praxis Precision MedicinesPRAX · Health Care | SAR 224.2M | SAR 32B | SAR 1,144.28 | 1.68% down | 61% up | ||
| 56 | Protagonist TherapeuticsPTGX · Health Care | SAR 200.6M | SAR 30.5B | SAR 467.64 | 0.13% down | 46% up | ||
| 57 | Dianthus TherapeuticsDNTH · Health Care | SAR 140.7M | SAR 18.4B | SAR 326.26 | 2.87% down | 113% up | ||
| 58 | Edgewise TherapeuticsEWTX · Health Care | SAR 113.8M | SAR 17.3B | SAR 157.69 | 3.75% down | 88% up | ||
| 59 | Oruka TherapeuticsORKA · Health Care | SAR 62.6M | SAR 24.5B | SAR 361.30 | 2.94% down | 241% up | ||
| 60 | Belite BioBLTE · Health Care | SAR 37.8M | SAR 24B | SAR 591.61 | 2.98% down | 31% up | ||
| 61 | VeradermicsMANE · Health Care | SAR 34.3M | SAR 19.9B | SAR 471.28 | 1.88% down | 233% up |
Sources: share prices and market values from Yahoo Finance; sector, country and category from each company's SEC registration; annual figures from the reports companies file with the SEC.
Market value is share price × shares outstanding, from Yahoo Finance; prices may be delayed 15 minutes or more and the ranking refreshes about every 20 minutes. The list covers companies with shares listed in the US, which includes foreign companies listed through ADRs but not ones listed only abroad. Sector, category and country come from each company's SEC registration. Total liabilities is from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day, not of the period. Where a company reports no total-liabilities line, it is worked out as assets less equity. Sums are converted from US dollars at today's exchange rate (1 USD = 3.7510 SAR).
Questions and answers
Which pharmaceuticals rank first by total liabilities?
AbbVie (SAR 514.6B), Pfizer (SAR 455.3B) and Johnson & Johnson (SAR 441.4B) are the top three of the 61 pharmaceuticals ranked by total liabilities as of 18 Nov 2026, 14:28 UTC.
How many pharmaceuticals are in this ranking?
61 are ranked by total liabilities.
What are these pharmaceuticals worth together?
The 61 pharmaceuticals ranked by total liabilities have a combined market value of SAR 19.35T as of 18 Nov 2026, 14:28 UTC.
What does ranking by total liabilities measure?
Everything the company owes, as its balance sheet stood at the end of the latest fiscal year.
Learn how this ranking works
All markets guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Market cap vs enterprise value: what is the difference?
Market capitalization is the value of a company's shares. Enterprise value is market cap plus debt, minus cash: roughly what it would cost to buy the whole business and settle its borrowings. Two companies with the same $50 billion market cap can have very different enterprise values if one owes $20 billion and the other holds $20 billion in cash.
- How an ETF's size is measured: AUM, NAV and creation units
An ETF's size is usually measured by its assets under management (AUM), the fund's net assets: everything it holds minus what it owes. That equals net asset value per share times shares outstanding. AUM grows when the holdings rise in value and when large institutions create new shares, and shrinks when they redeem them.
Cite this page
Funkfolio, “Largest pharmaceuticals by total liabilities”, data as of 18 November 2026. https://funkfolio.com/companies/category/pharmaceuticals?by=total-liabilities
Underlying data: Yahoo Finance; SEC EDGAR.